
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is expanding its total addressable market through the development of a feline assay, which is expected to significantly enhance revenue opportunities, particularly in the rapidly growing sector of feline oncology. The company has made noteworthy strides in commercialization, evidenced by the successful launch of its CE-Marked Nu.Q NETs automated assays in over 20 hospitals across multiple countries, and partnerships with industry leaders like Werfen and Hologic that are expected to bolster its human diagnostics strategy. Additionally, advancements in scientific validation and a strong market presence, particularly with the Nu.Q Vet Cancer Test, position VolitionRX favorably for sustained growth and recurring revenue generation across its diagnostic platforms.
Bears say
VolitionRX Ltd faces heightened dilution risk, which has negatively impacted its financial outlook as reflected in a reduced price target forecast from $5.00 to $3.00. This dilution risk may arise from potential additional capital raising efforts needed to fund operations and development within the highly competitive field of diagnostics. Consequently, this scenario contributes to uncertainty regarding shareholder value and overall market confidence in the company's growth prospects.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares